Countervail Corporation


Countervail’s principal investigator presents at 2009 NINDS CounterACT meeting in Washington, DC. Dr. Edson Albuquerque presents additional data on galantamine’s effectiveness in preserving survival and prevention of neural cell damage from nerve agent exposure.

Dr. Edson Albuquerque (MD,PhD), Chair of the Department of Pharmacology and Experimental Therapy at the University of Maryland School of Medicine in Baltimore, MD is a renowned neuropharmacologist and an expert on the use of galantamine as a countermeasure to organophosphate poisoning. The CounterACT Program at the NIH National Institute of Neurological Disorders and Stroke facilitates the research and development of medical countermeasures targeted toward chemical threats. At the annual CounterACT meeting Dr. Albuquerque presented additional data that was well received on the effectiveness of galantamine as a medical countermeasure against nerve agent poisoning.